Combined action of Silymarin and Celecoxib in modulating inflammatory mediators in osteoarthritis

Biomedicine and Preventive Nutrition

Volumn 4, Issue 4, 2014, Pages 485-490

  Ashkavand, Z ^a   Malekinejad, H ^b   Vishwanath, B S ^a  

^a UNIVERSITY OF MYSORE   (India)

^b URMIA UNIVERSITY   (Iran)

Author keywords

Antiarthritic effect; Celecoxib; Inflammatory mediators; Osteoarthritis (OA); Silymarin

Indexed keywords

ALKALINE PHOSPHATASE; CELECOXIB; CYCLOOXYGENASE 2; REACTIVE OXYGEN METABOLITE; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARTHRITIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RAT; SYNOVIAL FLUID LEVEL; UPREGULATION;

EID: 84908498417     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2014.07.007     Document Type: Article

References (42)

1. Grotle M., Hagen K.B., et al. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol 2008, 35(4):677-684.
2. Chikanza I., Fernandes L. Novel strategies for the treatment of osteoarthritis. Expert Opin Investig Drugs 2000, 9(7):1499-1510.
3. Fernandes J.C., Martel-Pelletier J., et al. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39(1):237-246.
4. Calich A.L.G., Domiciano D.S., et al. Osteoarthritis: can anti-cytokine therapy play a role in treatment?. Clin Rheumatol 2010, 29(5):451-455.
5. Middleton E., Kandaswami C., et al. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000, 52(4):673-751.
6. Ramasamy K., Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008, 269(2):352-362.
7. Hadaruga D., Hadaruga N. Antioxidant activity of hepatoprotective Silymarin and Silybum marianum L. extract. Chem Bull Politehn Univ Timisoara Rom Ser Chem Environ Eng 2009, 54(68):2.
8. Malekinejad H., Rahmani F., et al. Long-term administration of Silymarin augments pro-inflammatory mediators in the hippocampus of rats: evidence for antioxidant and pro-oxidant effects. Hum ExpToxicol 2012, 31(9):921-930.
9. Kalbhen D. Chemical model of osteoarthritis a pharmacological evaluation. J Rheumatol 1978, 14:130.
10. Bove S., Calcaterra S., et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003, 11(11):821-830.
11. Lawrence J. The epidemiology of chronic rheumatism. Ann Rheum Dis 1964, 23(1):81.
12. Schlebusch H., Rick W., et al. Standards in the activities of clinically important enzymes. Dtsch Med Wochenschr 1974, 99(15):765.
13. Chandrashekar K. d-Aspartic acid induced oxidative stress and mitochondrial dysfunctions in testis of prepubertal rats. Amino Acids 2010, 38(3):817-827.
14. Lowry O.H., Rosebrough N.J., et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193(1):265-275.
15. Zhou M., Diwu Z., et al. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem 1997, 253(2):162.
16. Guingamp C., Gegout-Pottie P., et al. Mono-iodoacetate-induced experimental osteoarthritis. A dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum 2005, 40(9):1670-1679.
17. Scott D., Pugner K., et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000, 39(2):122-132.
18. Guglielmi G., Scalzo G., et al. Imaging of the sacroiliac joint involvement in seronegative spondylarthropathies. Clin Rheumatol 2009, 28(9):1007-1019.
19. Boers M., Tugwell P., et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994, Supplement 41:86.
20. Ory P. Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis 2003, 62(7):597-604.
21. Ashkavand Z., Malekinejad H., et al. Silymarin potentiates the anti-inflammatory effects of Celecoxib on chemically induced osteoarthritis in rats. Phytomedicine 2012, 19(13):1200-1205. [15].
22. Reid C.L., Perrey C., et al. Genetic variation in pro-inflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med 2002, 30(10):2216-2221.
23. Altindag O., Erel O., et al. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int 2007, 27(4):339-344.
24. Darlington L.G., Stone T.W. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br J Nutr 2001, 85(3):251-269.
25. Narendhirakannan R., Subramanian S., et al. Free radical scavenging activity of Cleome gynandra L. leaves on adjuvant induced arthritis in rats. Mol Cell Biochem 2005, 276(1):71-80.
26. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J Clin Investig 2001, 107(1):7-12.
27. Miossec P. An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol 2004, 16(3):218-222.
28. Feldmann M., Brennan F., et al. The role of TNF and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 2001, 3:188-199.
29. Kamezaki F., Yamashita K., et al. Derivatives of reactive oxygen metabolites correlates with high-sensitivity C-reactive protein. J Atheroscler Thromb 2008, 15(4):206.
30. Shah R., Raska K., et al. The presence of molecular markers of in vivo lipid peroxidation in osteoarthritic cartilage: a pathogenic role in osteoarthritis. Arthritis Rheum 2005, 52(9):2799-2807.
31. Filippin L.I., Vercelino R., et al. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol 2008, 152(3):415-422.
32. Taysi S., Polat F., et al. Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int 2002, 21(5):200-204.
33. Ashkavand Z., Malekinejad H., et al. Silymarin potentiates the anti-inflammatory effects of Celecoxib on chemically induced osteoarthritis in rats. Phytomedicine 2012, 15:19(13):1200-1205.
34. Singer F.R., Eyre D.R. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008, 75(10):739-750.
35. Kumar V.S., Kumar D.A., et al. Optimization of pulsed electromagnetic field therapy for management of arthritis in rats. Bioelectromagnetics 2005, 26(6):431-439.
36. Yudoh K., Shishido K., et al. Water-soluble C60 fullerene prevents degeneration of articular cartilage in osteoarthritis via down-regulation of chondrocyte catabolic activity and inhibition of cartilage degeneration during disease development. Arthritis Rheum 2007, 56(10):3307-3318.
37. Zhang W., Nuki G., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18(4):476-499.
38. Jordan K., Arden N., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62(12):1145-1155.
39. Grösch S., Tegeder I., et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001, 15(14):2742-2744.
40. Hu W., Guo Z., et al. Discovery of 2-Phenyl-3-sulfonylphenyl-indole derivatives as a new class of selective COX-2 inhibitors. Bioorg Med Chem 2003, 11(24):5539-5544.
41. Queiroga F., Alves A., et al. Expression of Cox-1 and Cox-2 in canine mammary tumours. J Comp Pathol 2007, 136(2):177-185.
42. Uefuji K., Ichikura T., et al. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000, 6(1):135-138.